Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on Hard-to-Treat cancers in early trial

NCT ID NCT07638371

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack cancer cells. The main goal is to check safety, and the study is currently recruiting 16 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MSK-TCR5 (modified T-cells)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific genetic mutation (RAS G12D).
What could go wrong
This is an early phase 1 trial with only 16 participants, focused on safety. It is too small and early to know if the therapy works, and there are risks of side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR SOLID CARCINOMA SOLID TUMOR UNRESECTABLE SOLID TUMOR

Contacts and locations

Locations

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    RECRUITING

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    RECRUITING

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Nassau (Limited Protocol Activities)

    RECRUITING

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited Protocol Activities)

    RECRUITING

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    RECRUITING

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    RECRUITING

    Harrison, New York, 10604, United States

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

    RECRUITING

    Basking Ridge, New Jersey, 07920, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.